Keloid Treatment

Global Keloid Treatment Market to Reach US$4.1 Billion by 2030

The global market for Keloid Treatment estimated at US$3.6 Billion in the year 2024, is expected to reach US$4.1 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Occlusive Dressing, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Compression Therapy segment is estimated at 1.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$980.6 Million While China is Forecast to Grow at 4.1% CAGR

The Keloid Treatment market in the U.S. is estimated at US$980.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$767.5 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Keloid Treatment Market – Key Trends & Drivers Summarized

Why Is Keloid Treatment Becoming a Priority in Dermatological and Aesthetic Medicine?

Keloids are abnormal, fibrous overgrowths that occur at the site of skin injuries, often extending beyond the original wound margin and persisting long after the initial trauma has healed. While they are benign, keloids can be physically uncomfortable and psychologically distressing due to their raised, discolored, and sometimes painful nature. The increasing demand for both therapeutic and aesthetic solutions for keloids is propelling growth in the global treatment market, especially as awareness of skin health and cosmetic dermatology expands across diverse populations.

These lesions disproportionately affect individuals with darker skin types, particularly in populations of African, Asian, and Latin American descent, where genetic predisposition plays a significant role. As global health systems become more inclusive of ethnic dermatology, the need for targeted, evidence-based keloid treatments is rising. Keloid management typically requires a multimodal approach, as the condition has a high recurrence rate and variable response to therapy. The demand for effective, minimally invasive, and long-lasting treatments is therefore driving both clinical research and innovation in dermatological practices.

What Are the Leading Modalities in Keloid Management and How Are They Evolving?

The treatment of keloids involves a variety of approaches, ranging from conventional therapies to emerging technologies. First-line treatments often include corticosteroid injections, which reduce inflammation and collagen synthesis, helping to flatten and soften the scar over time. These may be combined with 5-fluorouracil (5-FU) or bleomycin to enhance efficacy. Cryotherapy, which uses liquid nitrogen to freeze and reduce the volume of keloid tissue, is frequently employed for smaller lesions or in conjunction with intralesional therapy.

Laser therapy—particularly pulsed dye lasers (PDL) and fractional CO2 lasers—is gaining popularity for improving keloid texture, color, and discomfort while stimulating collagen remodeling. Surgical excision, while sometimes necessary, carries a high risk of recurrence unless paired with adjunct therapies like radiation, pressure therapy, or silicone gel sheeting. More recent developments include the use of botulinum toxin injections to reduce mechanical tension at wound edges and the application of stem cell-based or gene-modifying treatments aimed at addressing the underlying fibroproliferative processes. These innovations are expanding the keloid treatment landscape beyond symptom suppression toward long-term management and prevention.

Which Patient Groups and Clinical Practices Are Driving Market Demand for Keloid Solutions?

Patients seeking keloid treatment span both medical and cosmetic domains, with individuals motivated by physical symptoms such as itching, burning, or restricted movement, as well as psychological distress and cosmetic concerns. Younger patients, particularly in the 20–40 age group, are key drivers of demand due to higher engagement with aesthetic procedures and personal care. Post-surgical and post-trauma patients, including those recovering from piercings, burns, and acne, represent another significant user base.

Dermatologists, plastic surgeons, oncologic surgeons, and aesthetic medicine practitioners are increasingly incorporating keloid management into their clinical offerings. The rise of teledermatology and digital consultation platforms is making expert care more accessible, especially in underserved regions where specialist skin care was previously limited. Medical spas, outpatient clinics, and cosmetic surgery centers are also contributing to market expansion by offering minimally invasive treatment packages, often combining laser therapy and injectables for comprehensive results. The shift in patient preference toward non-surgical, low-downtime interventions is shaping the delivery model of keloid care globally.

The Growth in the Keloid Treatment Market Is Driven by Several Factors…

The growth in the keloid treatment market is driven by several factors including the rising prevalence of hypertrophic scarring disorders, increasing awareness of skin health, and technological advancements in aesthetic dermatology. As populations age and undergo more surgeries and aesthetic procedures, the incidence of post-operative and trauma-related keloids is rising, fueling the need for effective treatment protocols. The proliferation of laser-based platforms, biologics, and combination therapies is also improving clinical outcomes and patient satisfaction, further encouraging adoption.

The expanding cosmetic dermatology sector—particularly in emerging economies—is creating new opportunities for both established brands and novel entrants offering keloid-specific solutions. Regulatory approvals of new drug formulations, enhanced delivery systems for topical agents, and the growing role of personalized treatment planning through AI and imaging tools are also contributing to market momentum. Furthermore, the integration of keloid treatment into comprehensive scar management and aesthetic restoration services is broadening its appeal across healthcare and beauty disciplines. As demand for skin condition correction continues to grow, the keloid treatment market is positioned for sustained innovation and commercial expansion.

SCOPE OF STUDY:

The report analyzes the Keloid Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment (Occlusive Dressing, Compression Therapy, Cryosurgery, Excision, Other Treatments); End-Use (Hospitals, Dermatology Clinics, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Avita Medical Limited
• Bausch Health Companies Inc.
• Bristol-Myers Squibb Company
• CellResearch Corporation
• Cynosure
• Enaltus LLC
• GlaxoSmithKline plc
• Hoffmann-La Roche Ltd.
• Kissei Pharmaceutical Co., Ltd.
• Lumenis
• Merck & Co., Inc.
• Mylan N.V. (now part of Viatris)
• Novartis AG
• Pacific World Corporation
• Perrigo Company plc
• Pfizer Inc.
• Revitol Corporation
• RXi Pharmaceuticals, Inc.
• Sensus Healthcare
• Sonoma Pharmaceuticals, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.